Heart Failure,Congestive Clinical Trial
— EMPA-RESPONSEOfficial title:
Randomized, Double Blind, Placebo Controlled, Multicenter Pilot Study on the Effects of Empagliflozin on Clinical Outcomes in Patients With Acute Decompensated Heart Failure (EMPA-RESPONSE-AHF)
Verified date | April 2024 |
Source | University Medical Center Groningen |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Acute decompensated heart failure is the fastest growing disease in the world and the leading cause of hospital admissions worldwide. Short term mortality and rehospitalization are extremely high (20-30% within 3-6 months) and there is no therapy available that improves clinical outcome in these patients. Empagliflozin is a selective inhibitor of sodium glucose co-transporter with diuretic and renal- protective properties. In patients with type 2 diabetes at high risk for cardiovascular events, empagliflozin reduced the risk of hospitalization for heart failure by 35%. Based on the promising pharmacological profile of empagliflozin in relation to the needs for treatment of acute decompensated heart failure, we hypothesize that empagliflozin exerts positive effects in acute decompensated heart failure, with or without diabetes, This is a randomized, placebo-controlled, double-blind, parallel group, multicenter study in subjects admitted for acute decompensated heart failure. Eighty eligible subjects will be randomized in a 1:1 ratio to receive either empagliflozin 10 mg/day or matched placebo.
Status | Completed |
Enrollment | 80 |
Est. completion date | September 18, 2019 |
Est. primary completion date | September 18, 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Male or female >18 years of age; Women of non-child-bearing potential must have a documentation of surgical sterilization (hysterectomy and/or bilateral oophorectomy) OR must have experienced menopause (no menses for >12 months). Women of child bearing potential must have a negative pregnancy test, AND must use highly effective methods of contraception during treatment with IP plus 5 days after the end of study drug administration. - Hospitalized for AHF; AHF is defined as including all of the followings measured at any time between presentation (including the emergency department) and the end of screening: 1. Dyspnea at rest or with minimal exertion 2. Signs of congestion, such as edema, rales, and/or congestion on chest radiograph 3. BNP =350 pg/mL or NT-proBNP =1,400 pg/mL (for patients with AF: BNP=500 pg/mL or NT-proBNP =2,000 pg/mL) 4. Treated with loop diuretics at screening - Able to be randomized within 24 hours from presentation to the hospital - Able and willing to provide freely given written informed consent - eGFR (CKD-EPI) =30 ml/min/1.73m2 between presentation and randomization Exclusion Criteria: - Diabetes Mellitus Type I - Dyspnea primarily due to non-cardiac causes - Cardiogenic shock - Acute coronary syndrome within 30 days prior to randomization - Planned or recent percutaneous or surgical coronary intervention within 30 days prior to randomization - Signs of keto-acidosis and/or hyperosmolar hyperglaecemic syndrome (pH>7.30 and glucose >15 mmol/L and HCO3>18 mmol/L) - Pregnant or nursing (lactating) women - Current participation in any interventional study - Inability to follow instructions or comply with follow-up procedures - Any other medical conditions that may put the patient at risk or influence study results in the investigator's opinion, or that the investigator deems unsuitable for the study. |
Country | Name | City | State |
---|---|---|---|
Netherlands | Jeroen Bosch Ziekenhuis | Den Bosch | Brabant |
Netherlands | TREANT Zorggroep | Emmen | Drenthe |
Netherlands | University Medical Center Groningen | Groningen | |
Netherlands | Antonius Ziekenhuis | Sneek | Friesland |
Netherlands | ISALA Klinieken | Zwolle | Overijssel |
Lead Sponsor | Collaborator |
---|---|
University Medical Center Groningen |
Netherlands,
Wanner C, Inzucchi SE, Lachin JM, Fitchett D, von Eynatten M, Mattheus M, Johansen OE, Woerle HJ, Broedl UC, Zinman B; EMPA-REG OUTCOME Investigators. Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. N Engl J Med. 2016 Jul 28;375(4):323-34. doi: 10.1056/NEJMoa1515920. Epub 2016 Jun 14. — View Citation
Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE; EMPA-REG OUTCOME Investigators. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015 Nov 26;373(22):2117-28. doi: 10.1056/NEJMoa1504720. Epub 2015 Sep 17. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Serious Adverse Events | SAE including all cause mortality. Per request Clintrials.gov different from Protocol definition | 60 days | |
Primary | Dyspnea | Change in Dyspnea on VAS analogue scale (AUC)
VAS Score is a measure/scale where patients on a scale from 0 to 100 can assign their current dyspnea score. 0 means there can be no worse dyspnea, 100 means it cannot get any better (perfect). The change in Dyspnea VAS means higher score is better outcomes. Individual changes in VAS score are be visualized (virtually) as a curve where the X-axis shows study day baseline to day 4, and y-axis shows VAS score. Using this approach, area under the curves for each study day (trapezoids) can be calculated, and added together, resulting in an overall VAS AUC score (mmxh) and change in VAS can be caculated |
From baseline to Day 4 | |
Primary | Diuretic Response | Weight change from baseline per 40 mg of Furosemide equivalent | Total weight change from baseline to Day 4 | |
Primary | Length of Stay | Hospital stay of Index admission | within 60 days | |
Primary | Plasma NTproBNP | Change in NTproBNP | From baseline to Day 4 | |
Secondary | Death and/or Heart Failure Re-admission | Death and/or heart failure re-admission at day 30 | Day 30 | |
Secondary | Inhospital Worsening Heart Failure, All Cause Mortality or Heart Failure Readmission at Day 60 | Inhospital Worsening Heart Failure or All Cause mortality or Heart Failure Readmission at day 60 | 60 days | |
Secondary | All Cause Mortality | All Cause Mortality at 60 days | 60 day |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03727646 -
Nicotinamide Riboside in LVAD Recipients
|
Early Phase 1 | |
Withdrawn |
NCT03519477 -
Comprehensive Medication Monitoring on Heart Failure Patient Outcomes
|
N/A | |
Recruiting |
NCT05596760 -
Promoting Goals-of-Care Discussions for Patients With Memory Problems and Their Caregivers
|
N/A | |
Recruiting |
NCT05227872 -
PVF in Decongestion of Heart Failure
|
||
Recruiting |
NCT05543720 -
Evaluation of Nurse-led Integrated Care of Complex Patients Facilitated By Telemonitoring: The SMaRT Study
|
N/A | |
Completed |
NCT04572425 -
Virtual Reality for Pain Management in Advanced Heart Failure
|
N/A | |
Recruiting |
NCT03202329 -
Evaluation of Post-operative, Nurse-based Heart Failure Care in Non-cardiac Surgery
|
N/A | |
Recruiting |
NCT03830957 -
Efficacy and Safety of Ivabradine to Reduce Heart Rate Prior to Coronary CT-angiography in Advanced Heart Failure: Comparison With β-Blocker
|
N/A | |
Recruiting |
NCT02672618 -
Clinical Research to Explore Manifestations of Heart Failure Using Infrared Thermal Imaging Technology
|
N/A | |
Recruiting |
NCT04179643 -
NAN-101 in Patients With Class III Heart Failure
|
Phase 1 | |
Completed |
NCT04129658 -
Heart Failure in Southern Sweden
|
||
Not yet recruiting |
NCT05591443 -
Artificial Intelligence and Smart Wearable Technologies for Early Detection of Acute Heart Failure
|
||
Completed |
NCT03387813 -
Hemodynamic-GUIDEd Management of Heart Failure
|
N/A | |
Completed |
NCT04628325 -
Effects of Furosemide Plus Small HSS in Subjects With Heart Failure With Reduced Ejection Fraction (HFrEF)
|
Phase 3 | |
Completed |
NCT03187470 -
Left Ventricular Dyssynchrony in Multipole Pacing
|
N/A | |
Completed |
NCT03385837 -
Activity Level and Barriers to Participate of Cardiac Rehabilitation in Advanced Heart Failure Patients
|
||
Completed |
NCT04281849 -
Balance, Aerobic Capacity, Mobility and Strength in Patients Hospitalized for Heart Failure (BAMS-HF) Program
|
N/A | |
Not yet recruiting |
NCT04403659 -
Telemonitoring of Patients Admitted in Hospital at Home With Acute Decompensated Heart Failure - Pilot Study
|
N/A | |
Terminated |
NCT04142788 -
RELieving Increasing oEdema Due to Heart Failure
|
Phase 4 | |
Active, not recruiting |
NCT04283994 -
Project to Improve Communication About Serious Illness--Hospital Study: Comparative Effectiveness Trial (Trial 2)
|
N/A |